Zandelisib + Rituximab + Bendamustine + CHOP
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma (FL)
Conditions
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
Trial Timeline
Aug 13, 2021 → Mar 20, 2023
NCT ID
NCT04745832About Zandelisib + Rituximab + Bendamustine + CHOP
Zandelisib + Rituximab + Bendamustine + CHOP is a phase 3 stage product being developed by Kyowa Kirin for Follicular Lymphoma (FL). The current trial status is terminated. This product is registered under clinical trial identifier NCT04745832. Target conditions include Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04745832 | Phase 3 | Terminated |
Competing Products
20 competing products in Follicular Lymphoma (FL)